Opinion
Video
Study Design: Comparing the ARCHES and ARANOTE trials
Author(s):
A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in both metastatic and nonmetastatic patients, whereas ARANOTE specifically studied apalutamide plus ADT vs ADT alone in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.
Summary for Physicians: Limitations of MAIC Analyses
Summary for Physicians: ARCHES vs. ARANOTE Trial Designs
The ARCHES and ARANOTE trials differ substantially in their fundamental design elements:
ARCHES Trial:
- Evaluated enzalutamide plus ADT vs placebo plus ADT
- Included both metastatic and nonmetastatic patient populations
ARANOTE Trial:
- Evaluated apalutamide plus ADT vs ADT alone
- Specifically focused on patients with newly diagnosed metastatic hormone-sensitive prostate cancer only
These design differences should be considered when interpreting and comparing results between these 2 androgen receptor pathway inhibitor trials.
